These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 28347512)

  • 1. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
    Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
    Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
    Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
    Crumley S; Kurnit K; Hudgens C; Fellman B; Tetzlaff MT; Broaddus R
    Mod Pathol; 2019 Mar; 32(3):396-404. PubMed ID: 30291344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Kim J; Kim S; Lee HS; Yang W; Cho H; Chay DB; Cho SJ; Hong S; Kim JH
    Gynecol Oncol; 2018 May; 149(2):381-387. PubMed ID: 29572029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
    Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
    Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
    Engerud H; Berg HF; Myrvold M; Halle MK; Bjorge L; Haldorsen IS; Hoivik EA; Trovik J; Krakstad C
    Gynecol Oncol; 2020 Apr; 157(1):260-267. PubMed ID: 31973911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
    Miyatake T; Tringler B; Liu W; Liu SH; Papkoff J; Enomoto T; Torkko KC; Dehn DL; Swisher A; Shroyer KR
    Gynecol Oncol; 2007 Jul; 106(1):119-27. PubMed ID: 17509674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
    Guo L; Liu Z; Zhang Y; Quan Q; Huang L; Xu Y; Cao L; Zhang X
    Medicine (Baltimore); 2019 Feb; 98(8):e14663. PubMed ID: 30813210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
    Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
    Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.